Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
Earnings Data
Report Date
Mar 18, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.09Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive progress in revenues, R&D advancements, and strategic partnerships, while also highlighting challenges such as decreased cash reserves and the need for FDA feedback for key products. Overall, the positive aspects of the company's progress and strategic focus on future opportunities suggest a cautiously optimistic outlook.Company Guidance
Significant Revenue Increase
Total revenue for Q3 2025 was $14.2 million, a substantial increase from $1.8 million in Q3 2024, primarily due to $13.2 million of licensing revenue from Novo Nordisk.
Progress in R&D and Strategic Partnerships
Completion of IND-enabling studies for LX9851 in obesity; ongoing discussions with potential partners for pilavapadin; partnership with Viatris expanding SOTA's reach in major markets.
Operational Efficiency and Cost Reduction
Operating expenses decreased by $39.1 million quarter-over-quarter due to strategic repositioning as an R&D-focused company.
Advancements in Clinical Trials
All 130-plus sites active in the Phase III SONATA study for sotagliflozin in HCM; successful progress in pilavapadin's Phase II trials indicating readiness for Phase III.
Positive Developments in Pain Management Legislation
Lexicon's advocacy efforts led to the introduction of the Relief of Chronic Pain Act in the U.S. Senate, supporting non-opioid therapies.
LXRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LXRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $1.38 | $1.43 | +3.62% |
Aug 06, 2025 | $1.05 | $1.15 | +9.52% |
May 13, 2025 | $0.63 | $0.53 | -15.87% |
Mar 06, 2025 | $0.37 | $0.39 | +5.41% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lexicon Pharmaceuticals (LXRX) report earnings?
Lexicon Pharmaceuticals (LXRX) is schdueled to report earning on Mar 18, 2026, Before Open (Confirmed).
What is Lexicon Pharmaceuticals (LXRX) earnings time?
Lexicon Pharmaceuticals (LXRX) earnings time is at Mar 18, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LXRX EPS forecast?
LXRX EPS forecast for the fiscal quarter 2025 (Q4) is -0.07.